China is becoming an increasingly important source of drug development and licensing opportunities for global pharma. For BD&L and Search & Evaluation teams, the challenge is knowing where to look, which evidence matters, and which assets deserve a closer look.
In this webinar, we’ll discuss how AI agents can help teams find and evaluate drug assets in China. Using a real search for China-origin oral TYK2 inhibitors, we’ll walk through the findings, examine one candidate in more detail, and share practical lessons for your own scouting and due diligence.
Who this webinar is for
For teams evaluating drug assets in China:
- Business Development & Licensing
- Search & Evaluation and External Innovation
- Competitive Intelligence and Portfolio Strategy
- Biotech investing and scientific due diligence
What we’ll discuss
How scouting and due diligence are changing
The research that teams do by hand today, the work AI agents can support, and the decisions that remain with experts.
A real asset search in China
A case study of oral TYK2 inhibitors for plaque psoriasis, including the search criteria, Chinese-language sources, and the resulting asset landscape.
From a shortlist to due diligence
A closer look at ICP-488: what the clinical evidence supports, what remains unknown, and which questions to ask next.
Speakers
Tigran Lachinyan
Head of Business Development, BIOPTIC
Ilya Yasny, PhD
Partner and Head of Science, LanceBio
Join us live
·
28 Oct
·
16:00 London time (GMT)
·
12:00 New York (EDT)
Register for a webinar
English
·
Zoom
·
45 mins
·
Live Q&A